Index by author

December 01, 2009; Volume 76,Issue 12

B

  1. Bartholomew, John R.

    1. An algorithm for managing warfarin resistance
      Olusegun Osinbowale, MD, MBA, RPVI, Monzr Al Malki, MD, Andrew Schade, MD, PhD and John R. Bartholomew, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 724-730; DOI: https://doi.org/10.3949/ccjm.76a.09062

      Some patients need higher-than-expected doses of warfarin to reach their target INR. The cause can be acquired (poor compliance, drug interactions) or hereditary.

C

  1. Coco, Maria

    1. Treating the renal patient who has a fracture: Opinion vs evidence
      Maria Coco, MD, MS
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 684-688; DOI: https://doi.org/10.3949/ccjm.76a.09075

      The patient with chronic renal disease who has a fracture remains a unique management challenge. Opinions on treatment abound, but without adequate evidence to back them up.

L

  1. Lazar, Lawrence D.

    1. Prasugrel for acute coronary syndromes: Faster, more potent, but higher bleeding risk
      Lawrence D. Lazar, MD and A. Michael Lincoff, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 707-714; DOI: https://doi.org/10.3949/ccjm.76a.09116

      Prasugrel (Effient) is faster and more consistent in its effects, but patients at high bleeding risk should still receive clopidogrel (Plavix).

  2. Lincoff, A. Michael

    1. Prasugrel for acute coronary syndromes: Faster, more potent, but higher bleeding risk
      Lawrence D. Lazar, MD and A. Michael Lincoff, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 707-714; DOI: https://doi.org/10.3949/ccjm.76a.09116

      Prasugrel (Effient) is faster and more consistent in its effects, but patients at high bleeding risk should still receive clopidogrel (Plavix).

M

  1. Malki, Monzr Al

    1. An algorithm for managing warfarin resistance
      Olusegun Osinbowale, MD, MBA, RPVI, Monzr Al Malki, MD, Andrew Schade, MD, PhD and John R. Bartholomew, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 724-730; DOI: https://doi.org/10.3949/ccjm.76a.09062

      Some patients need higher-than-expected doses of warfarin to reach their target INR. The cause can be acquired (poor compliance, drug interactions) or hereditary.

  2. Mandell, Brian F.

    1. Low bone density is not always bisphosphonate deficiency
      Brian F. Mandell, MD, PhD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 683; DOI: https://doi.org/10.3949/ccjm/76a.12001

      Low bone density is not a one-size-fits-all disorder. We need to carefully consider the diagnostic and therapeutic options before assuming that low bone density is osteoporosis.

  3. Messerli, Franz H.

    1. Is an ACE inhibitor plus an ARB more effective than either drug alone?
      Franz H. Messerli, MD and Melana Yuzefpolskaya, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 693-696; DOI: https://doi.org/10.3949/ccjm.76a.09052

      No. Dual renin-angiotensin system blockade has never been shown to reduce the rates of morbidity or death from any cause.

  4. Miller, Paul D.

    1. Fragility fractures in chronic kidney disease: An opinion-based approach
      Paul D. Miller, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 715-723; DOI: https://doi.org/10.3949/ccjm.76a.08108

      When a patient with chronic kidney disease suffers a fragility fracture, a key question is whether the patient has osteoporosis or, instead, renal osteodystrophy. Bone densitometry does not help in this distinction.

O

  1. Osinbowale, Olusegun

    1. An algorithm for managing warfarin resistance
      Olusegun Osinbowale, MD, MBA, RPVI, Monzr Al Malki, MD, Andrew Schade, MD, PhD and John R. Bartholomew, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 724-730; DOI: https://doi.org/10.3949/ccjm.76a.09062

      Some patients need higher-than-expected doses of warfarin to reach their target INR. The cause can be acquired (poor compliance, drug interactions) or hereditary.

P

  1. Parsi, Mansour A.

    1. Acute pancreatitis: Problems in adherence to guidelines
      Acute pancreatitis: Problems in adherence to guidelines
      Tyler Stevens, MD, Mansour A. Parsi, MD and R. Matthew Walsh, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 697-704; DOI: https://doi.org/10.3949/ccjm.76a.09060

      Evidence-based guidelines on managing acute pancreatitis are available, but many physicians are not following them.

S

  1. Schade, Andrew

    1. An algorithm for managing warfarin resistance
      Olusegun Osinbowale, MD, MBA, RPVI, Monzr Al Malki, MD, Andrew Schade, MD, PhD and John R. Bartholomew, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 724-730; DOI: https://doi.org/10.3949/ccjm.76a.09062

      Some patients need higher-than-expected doses of warfarin to reach their target INR. The cause can be acquired (poor compliance, drug interactions) or hereditary.

  2. Stevens, Tyler

    1. Acute pancreatitis: Problems in adherence to guidelines
      Acute pancreatitis: Problems in adherence to guidelines
      Tyler Stevens, MD, Mansour A. Parsi, MD and R. Matthew Walsh, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 697-704; DOI: https://doi.org/10.3949/ccjm.76a.09060

      Evidence-based guidelines on managing acute pancreatitis are available, but many physicians are not following them.

W

  1. Walsh, R. Matthew

    1. Acute pancreatitis: Problems in adherence to guidelines
      Acute pancreatitis: Problems in adherence to guidelines
      Tyler Stevens, MD, Mansour A. Parsi, MD and R. Matthew Walsh, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 697-704; DOI: https://doi.org/10.3949/ccjm.76a.09060

      Evidence-based guidelines on managing acute pancreatitis are available, but many physicians are not following them.

Y

  1. Yuzefpolskaya, Melana

    1. Is an ACE inhibitor plus an ARB more effective than either drug alone?
      Franz H. Messerli, MD and Melana Yuzefpolskaya, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 693-696; DOI: https://doi.org/10.3949/ccjm.76a.09052

      No. Dual renin-angiotensin system blockade has never been shown to reduce the rates of morbidity or death from any cause.

Back to top

In this issue